

ESC/EASD 2025 HIGHLIGHTS



**Recorded Live on
SEPTEMBER 30**

7:00 – 8:30 pm EDT

Developed by:
 **CCRN**
Collaborative CME and Research Network

Program Overview:

This program covers key clinical trial findings and their implications from ESC and EASD 2025. This program is intended for cardiovascular specialists and primary care physicians.

Discussion Topics:

- Does tirzepatide reduce CV events?
- Does evolocumab improve bypass graft patency at 2 years?
- What's new in resistant/uncontrolled hypertension?
- What is the role of beta-blockers in post-MI patients with EF > 40%?

Learning Objectives:

Following participation in this program, participants will be able to:

- Identify the clinical implications of the new data presented at ESC and EASD 2025
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice



Watch the recording on CCRN website:

www.ccrnmd.com > Education > Webcasts



SPEAKERS



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)

Assistant Professor,
Department of Medicine,
University of Toronto
Medical Director,
Collaborative CME and Research Network
Brampton, ON



Narendra Singh

MD, FRCPC, FCCS, FACC, FAHA

Director, NSC Cardiology
Clinical Assistant Professor,
Medical College of Georgia at Augusta
University and Mercer University
Atlanta, GA

This program was developed by CCRN and received an unrestricted educational grant from Amgen, AstraZeneca and Eli Lilly.